150 related articles for article (PubMed ID: 26807235)
1. Amplification of the bromodomain-containing protein 4 gene in ovarian high-grade serous carcinoma is associated with worse prognosis and survival.
Ucar D; Lin DI
Mol Clin Oncol; 2015 Nov; 3(6):1291-1294. PubMed ID: 26807235
[TBL] [Abstract][Full Text] [Related]
2. Amplification of the
Jones DH; Lin DI
Mol Clin Oncol; 2017 Aug; 7(2):301-307. PubMed ID: 28781807
[TBL] [Abstract][Full Text] [Related]
3. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis.
Drumond-Bock AL; Bieniasz M
Mol Cancer; 2021 Nov; 20(1):145. PubMed ID: 34758842
[TBL] [Abstract][Full Text] [Related]
4. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
6. Clinical perspectives of BET inhibition in ovarian cancer.
Andrikopoulou A; Liontos M; Koutsoukos K; Dimopoulos MA; Zagouri F
Cell Oncol (Dordr); 2021 Apr; 44(2):237-249. PubMed ID: 33469840
[TBL] [Abstract][Full Text] [Related]
7. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma.
Baratta MG; Schinzel AC; Zwang Y; Bandopadhayay P; Bowman-Colin C; Kutt J; Curtis J; Piao H; Wong LC; Kung AL; Beroukhim R; Bradner JE; Drapkin R; Hahn WC; Liu JF; Livingston DM
Proc Natl Acad Sci U S A; 2015 Jan; 112(1):232-7. PubMed ID: 25535366
[TBL] [Abstract][Full Text] [Related]
8. Recurrent Somatic Copy Number Alterations and Their Association with Oncogene Expression Levels in High-Grade Ovarian Serous Carcinoma.
Esplen HP; Yang RK; Kalia A; Tang Z; Tang G; Medeiros LJ; Toruner GA
Life (Basel); 2023 Nov; 13(11):. PubMed ID: 38004332
[TBL] [Abstract][Full Text] [Related]
9. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
10. High-grade serous ovarian and fallopian tube carcinomas with similar clinicopathological characteristics might originate from serous tubal intraepithelial carcinoma in Chinese women.
Wang J; Wu H; Zhang Y; Zhang Y; Li X; Zhao Q; Meng F; Huang Q; Wang Y
Int J Clin Exp Pathol; 2017; 10(8):8222-8232. PubMed ID: 31966673
[TBL] [Abstract][Full Text] [Related]
11. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma.
Kurman RJ
Ann Oncol; 2013 Dec; 24 Suppl 10():x16-21. PubMed ID: 24265397
[TBL] [Abstract][Full Text] [Related]
12. CD105 Is Expressed in Ovarian Cancer Precursor Lesions and Is Required for Metastasis to the Ovary.
Bai S; Zhu W; Coffman L; Vlad A; Schwartz LE; Elishaev E; Drapkin R; Buckanovich RJ
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31684072
[No Abstract] [Full Text] [Related]
13. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
14. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
15. Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma.
Sakaguchi T; Yoshino H; Sugita S; Miyamoto K; Yonemori M; Osako Y; Meguro-Horike M; Horike SI; Nakagawa M; Enokida H
Oncotarget; 2018 May; 9(33):23003-23017. PubMed ID: 29796168
[TBL] [Abstract][Full Text] [Related]
16. [Oncopathological aspects of BRCA1 and BRCA2 genes inactivation in tumors of ovary, fallopian tube and pelvic peritoneum].
Škapa P; Dundr P
Cesk Patol; 2016; 52(4):199-204. PubMed ID: 27869446
[TBL] [Abstract][Full Text] [Related]
17. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
18. Cell Origins of High-Grade Serous Ovarian Cancer.
Kim J; Park EY; Kim O; Schilder JM; Coffey DM; Cho CH; Bast RC
Cancers (Basel); 2018 Nov; 10(11):. PubMed ID: 30424539
[TBL] [Abstract][Full Text] [Related]
19. A BRCA1/2 Mutational Signature and Survival in Ovarian High-Grade Serous Carcinoma.
Dong F; Davineni PK; Howitt BE; Beck AH
Cancer Epidemiol Biomarkers Prev; 2016 Nov; 25(11):1511-1516. PubMed ID: 27496093
[TBL] [Abstract][Full Text] [Related]
20. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
